skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence

Original Research

(2118) Views  (700) Full article downloads

Authors: Todd Zorick, Rajkumar J Sevak, Karen Miotto, et al

Published Date December 2009 Volume 2010:2 Pages 13 - 18
DOI: http://dx.doi.org/10.2147/JEP.S8356

Todd Zorick1, Rajkumar J Sevak1, Karen Miotto1, Steven Shoptaw2,4, Aimee-Noelle Swanson2, Clayton Clement1, Richard De La Garza II1*, Thomas F Newton1*, Edythe D London1,3,4

1Departments of Psychiatry and Biobehavioral Sciences, 2Family Medicine, 3Molecular and Medical Pharmacology, 4The Brain Research Institute, University of California Los Angeles, Los Angeles, CA, USA; *Present address: Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA

Abstract: Despite the worldwide extent of methamphetamine dependence, no medication has been shown to effectively treat afflicted individuals. One relatively unexplored approach is modulation of cholinergic system function. Animal research suggests that enhancement of central cholinergic activity, possibly at nicotinic acetylcholine receptors (nAChRs), can reduce methamphetamine-related behaviors. Further, preliminary findings indicate that rivastigmine, a cholinesterase inhibitor, may reduce craving for methamphetamine after administration of the drug in human subjects. We therefore performed a double-blind, placebo-controlled, crossover pilot study of the safety and tolerability of varenicline in eight methamphetamine-dependent research subjects. Varenicline is used clinically to aid smoking cessation, and acts as a partial agonist at α4b2 nAChRs with full agonist properties at α7 nAChRs. Oral varenicline dose was titrated over one week to reach 1 mg twice daily, and then was co-administered with 30 mg methamphetamine, delivered in 10 intravenous (iv) infusions of 3 mg each. Varenicline was found to be safe in combination with iv methamphetamine, producing no cardiac rhythm disturbances or alterations in vital sign parameters. No adverse neuropsychiatric sequelae were detected either during varenicline titration or following administration of methamphetamine. The results suggest that varenicline warrants further investigation as a potential treatment for methamphetamine dependence.

Keywords: varenicline, methamphetamine, treatment, safety, nicotinic, acetylcholine








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose–insulin homeostasis in animal models
Effects of an oral dose of l-glutamic acid on circulating neurotransmitters: Possible roles of the C1(Ad) and the A5(NA) pontomedullary nuclei
Nephroprotection of lacidipine against gentamycin-induced nephrotoxicity in albino rats
ABO and rhesus blood group distribution in Kurds
Methemoglobinemia due to topical pharyngeal anesthesia during endoscopic procedures
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Effect of long-term treatment with eyedrops for glaucoma on conjunctival bacterial flora
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University